Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | IGF1R | P08069 | 3/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.38 |
| ▸ | PTK6 | Q13882 | 7/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4962614 | 0.89 | CHRM2 (0.40) | EGFRIGF1RPTK6ERBB2POLB | |
| SCHEMBL4958759 | 0.86 | AURKA (0.46) | EGFRIGF1RSPHK1SPHK2PTK6 | |
| SCHEMBL14594993 | 0.83 | SPHK1 (0.35) | SPHK1SPHK2MAPTPOLBALK | |
| SCHEMBL4960536 | 0.82 | EGFR (0.37) | EGFRIGF1RPTK6ERBB2UTS2R | |
| SCHEMBL4958627 | 0.82 | MEN1 (0.42) | SPHK1SPHK2MAPTPOLB | |
| SCHEMBL14594934 | 0.80 | ALK (0.47) | PTK6ERBB2ALK | |
| SCHEMBL4959129 | 0.79 | CHEK1 (0.41) | IGF1RSPHK1SPHK2MAPTPOLB | |
| SCHEMBL14626816 | 0.79 | ALK (0.46) | PTK6ERBB2ALK | |
| SCHEMBL14627335 | 0.78 | EGFR (0.34) | EGFRIGF1RPTK6ERBB2UTS2R | |
| SCHEMBL14594959 | 0.78 | ALK (0.45) | PTK6ERBB2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896472-A1 | ALPHA-CARBOLINES AS CDK-1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-20070004684-A1 | Alpha-Carbolines as CDK-1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004684-A1 | Alpha-Carbolines as CDK-1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004684-A1 | Alpha-Carbolines as CDK-1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-04 | — | — | US | disclosed |
| WO-2006131552-A1 | ALPHA-CARBOLINES AS CDK-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004684-A1 | Alpha-Carbolines as CDK-1 inhibitors | CDKL1, CDK1, CCNA1 | EGFR 1815/4885IGF1R 780/4885SPHK1 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.